Author | Neves, Josiane S. | |
Author | Lima, Lídia M. | |
Author | Fraga, Carlos A. M. | |
Author | Barreiro, Eliezer J. | |
Author | Miranda, Ana L. P. | |
Author | Diaz, Bruno L. | |
Author | Balduino, Alex | |
Author | Siqueira, Rodrigo de Azeredo | |
Author | Silva, Patrícia M. R. e | |
Author | Martins, Marco A. | |
Access date | 2019-12-19T13:54:00Z | |
Available date | 2019-12-19T13:54:00Z | |
Document date | 2005 | |
Citation | NEVES, Josiane S. et al. Evaluating the prophylatic potential ot the phtalimide derivative LASSBio 552 on allergen-evoked inflammatin in rats. European Journal of Pharmacology, v. 511, p. 219-227, 2005. | pt_BR |
ISSN | 0014-2999 | pt_BR |
URI | https://www.arca.fiocruz.br/handle/icict/38707 | |
Language | eng | pt_BR |
Publisher | Elsevier | pt_BR |
Rights | restricted access | pt_BR |
Subject in Portuguese | Eosinófilo | pt_BR |
Subject in Portuguese | Derivado de tetrazoleftalimida | pt_BR |
Subject in Portuguese | Leucotrieno | pt_BR |
Subject in Portuguese | Alergia | pt_BR |
Subject in Portuguese | LASSBio 552 | pt_BR |
Title | Evaluating the prophylactic potential of the phtalimide derivative LASSBio 552 on allergen-evoked inflammation in rats | pt_BR |
Type | Article | pt_BR |
DOI | 10.1016/j.ejphar.2005.02.011 | |
Abstract | A previous study showed that the novel tetrazolephtalimide derivative LASSBio 552 (2-4-[3-(1H-1,2,3,4-tetraazol-5-yl)propoxy]phenethyl-1,3-isoindolinedione) prevents LTD(4)-evoked tracheal contraction. This led us to examine the putative anti-inflammatory effect of LASSBio 552 in comparison with the leukotriene CysLT(1) receptor antagonist zafirlukast using a model of allergic pleurisy in rats. Treatment with either LASSBio 552 (24-96 micromol/kg, i.p.) or zafirlukast (9-72 micromol/kg, i.p.), 1 h before challenge, inhibited eosinophil and mononuclear cell influx into the pleural cavity 24 h post-challenge, but failed to alter the increased levels of eotaxin, plasma leakage, mast cell degranulation and neutrophil infiltration noted 6 h post-challenge. CD4(+) T cell recruitment 24 h post-challenge was also sensitive to LASSBio 552. This treatment failed to alter cysteinyl leukotriene production at 6 h, but clearly inhibited the phenomenon 24 h and 48 h post-challenge. In in vitro settings LASSBio 552 inhibited allergen-evoked cysteinyl leukotriene generation from isolated mast cells, while histamine release remained unchanged. It also slightly inhibited cysteinyl leukotriene production by eosinophils and mononuclear cells triggered by Ca(+2) ionophore A23187. A leukotriene CysLT(1) receptor transfected cell-based assay revealed that LASSBio 552 did not prevent LTD(4)-evoked Ca(+2) influx, indicating that it was not a leukotriene CysLT(1) receptor antagonist. These findings indicate that LASSBio 552 is able to inhibit eosinophil influx triggered by allergen chalenge in a mechanism at least partially associated with suppression of CD4(+) T cell influx and cysteinyl leukotriene production. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Departamento de Fisiologia e Farmacodinâmica. Rio de Janeiro, RJ, Brasil / Universidade Federal do Rio de Janeiro. Centro de Ciências Biomédicas. Departamento de Farmacologia Básica e Clínica. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Universidade Federal do Rio de Janeiro. Faculdade de Farmácia. Departamento de Fármacos. LASSBio. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Universidade Federal do Rio de Janeiro. Faculdade de Farmácia. Departamento de Fármacos. LASSBio. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Universidade Federal do Rio de Janeiro. Centro de Ciências Biomédicas. Departamento de Farmacologia Básica e Clínica. Rio de Janeiro, RJ, Brasil / Universidade Federal do Rio de Janeiro. Faculdade de Farmácia. Departamento de Fármacos. LASSBio. Rio de Janeiro, RJ, Brasil.. | pt_BR |
Affilliation | Universidade Federal do Rio de Janeiro. Faculdade de Farmácia. Departamento de Fármacos. LASSBio. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Instituto Nacional de Câncer. Coordenação de Pesquisa. Divisão de Biologia Celular. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Universidade Federal do Rio de Janeiro. Centro de Ciências Biomédicas. Departamento de Histologia e Embriologia. Ri de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Departamento de Fisiologia e Farmacodinâmica. Rio de Janeiro, RJ, Brasil / Universidade Federal do Rio de Janeiro. Centro de Ciências Biomédicas. Departamento de Farmacologia Básica e Clínica. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Departamento de Fisiologia e Farmacodinâmica. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Departamento de Fisiologia e Farmacodinâmica. Rio de Janeiro, RJ, Brasil. | pt_BR |
Subject | LASSBio 552 | pt_BR |
Subject | Tetrazolephtalimide derivative | pt_BR |
Subject | Leukotriene | pt_BR |
Subject | Eosinophil | pt_BR |
Subject | Allergy | pt_BR |
e-ISSN | 1879-0712 | |
Embargo date | 2025-01-01 | |